Search filters

Filters
Clear All

Phase

  • 1
  • 6
  • 9
  • 2
  • 19
  • 8
  • 19

Found 19 Non-Hodgkin's Lymphoma trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.
99 years or below
All genders
Phase 2
The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.
99 years or below
All genders
Phase 1
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
99 years or below
All genders
Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system. This increased cancer risk may be due to damage to cells in your gastrointestinal system that is caused at the time of radiation. This research is being …
18 years - 99 years
All genders
Phase 2
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
 A Randomized  Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines
18 years - 99 years
All genders
Phase 1
You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart …
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 Phase I Trial of Programmed Allogeneic CRISPR-edited T cells (PACE) Gene Edited to Eliminate Endogenous TCR  HLA-class I and HLA-class II and Engineered to Express anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma
18 years - 99 years
All genders
Phase 1
Interventional
This research study is being conducted to evaluate an experimental drug called PACE CART19 in patients with leukemia or lymphoma. PACE CART19 consists of cells from a healthy donor that are genetically modified and designed to target your cancer.
 A Randomized  Multicenter  Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
18 years - 99 years
All genders
Interventional
This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion …
11 - 19 of 19